Skip to main content

Commercializing Innovation: Prof. Doug Melton and Semma Therapeutics

April 24th, 2017 ~ 04:00pm–06:00pm
Biolabs 1080, 16 Divinity Ave., Cambridge, MA 02138

Register Here

Featuring cofounders of Harvard-launched startup Semma Therapeutics:

  • Douglas A. Melton, PhD, Xander University Professor and Thomas Dudley Cabot Professor in the Natural Sciences, Harvard University; co-director of the Harvard Stem Cell Institute
  • Felicia Pagliuca, PhD, Vice President of Cell Biology Research and Development, Semma Therapeutics
  • Robert Millman, JD, CEO of Semma Therapeutics

The Commercializing Innovation speaker series is primarily intended for Harvard University faculty, postdoctoral researchers, and graduate students who are interested in learning about technology commercialization, careers outside of academia, and scientific entrepreneurship. However, the event is open to all.

Hosted by Harvard Office of Technology Development and the FAS Office of Postdoctoral Affairs.


About Prof. Doug Melton

Dr. Douglas Melton is the Xander University Professor and Thomas Dud­ley Cabot Professor in the Natural Sciences at Harvard University. He is also a co-director of the Harvard Stem Cell Institute and scientific found­er of Semma Therapeutics. Research in the Melton Laboratory is focused on the developmental biology of the pancreas, with the aim of understanding the genes and cells that direct pancreatic organogenesis. Dr. Melton earned a bachelor’s degree in biology from the University of Illinois and then went to Cambridge University in England as a Marshall Scholar. He earned a BA in history and philosophy of science at Cam­bridge and remained there to earn a PhD in molecular biology at Trinity College and the MRC Laboratory of Molecular Biology.

About Semma Therapeutics

The following description is from the company's website, semma-tx.com.

Type 1 diabetes (T1D), formerly known as juvenile diabetes, is a chronic, life-threatening disease that affects millions of people worldwide. In the United States, 30,000 new cases are estimated every year with half of those cases diagnosed in young children. Type 1 diabetes is an autoimmune disease in which the patient’s immune system goes awry and attacks and destroys the pancreatic beta cells. Beta cells are responsible for regulating blood sugar (glucose) levels by producing precise amounts of the essential hormone insulin.

The discovery of injectable insulin in the 1920s changed T1D from a uniformly fatal disease with a life expectancy of months to one that could be carefully managed for decades through multiple daily blood glucose measurements and insulin injections. However, insulin injections are not a cure and patients face a lifetime of difficult disease management and serious complications including kidney failure, blindness and nerve damage. Despite nearly a century passing since the discovery of insulin, insulin injection remains the only treatment available to patients.

Semma Therapeutics was founded to develop transformative therapies for patients who currently depend on insulin injections. Recent work in the laboratory of Professor Douglas Melton led to the discovery of a method to generate billions of functional, insulin-producing beta cells in the laboratory. These cells develop in islet-like clusters grown from stem cells. Initial preclinical work in animal models of diabetes has shown that transplantation of these cells are sufficient to control blood glucose levels. This breakthrough technology has been exclusively licensed to Semma Therapeutics for the development of a cell-based therapy for diabetes.

Ongoing research at Semma Therapeutics is focused on combining these proprietary cells with a state-of-the-art cell delivery and immune protection strategy that can protect these cells from the patient’s immune system and allow the beta cells to function as they do in non-diabetic individuals. Implantation of the beta cell-filled device has the potential to provide a true replacement for the missing beta cells in a diabetic patient and would not require patient immunosuppression. Semma Therapeutics is working to bring this new therapeutic option to the clinic and improve the lives of patients with diabetes.

Press Contact

Caroline Perry
(617) 495-4157
Email